- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00739648
A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Efficacy of MP-376 Inhalation Solution Administered for 5 Days Every 28 Days to Prevent Acute Exacerbations in High Risk COPD Patients
Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent acute exacerbations (AECB) which are associated with enormous healthcare expenditures and significant morbidity, specifically an increased risk of death, a decline in pulmonary function and a significant change in quality of life. Bacteria appear to have an important role in acute exacerbations in chronic bronchitis and COPD. Studies of acute exacerbations in COPD have shown a reduction in bacterial load with prolonged exacerbation-free interval. In addition, recent studies indicate that acquisition of a new strain of H. influenzae, M. catarrhalis, S. pneumoniae or P. aeruginosa are responsible for many of these exacerbations. Chronic inflammation and bacterial infection predispose many patients to frequent and recurrent acute exacerbations.
Mpex believes that intermittent administration of inhaled MP-376 in high risk patients will decrease the incidence of acute exacerbations by both by lowering the organism burden, and resultant inflammation, as well as pre-emptive eradication of any newly acquired bacterial strains.
연구 개요
상세 설명
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
Alabama
-
Haleyville, Alabama, 미국, 35565
-
Hueytown, Alabama, 미국, 35023
-
Mobile, Alabama, 미국, 36608
-
Montgomery, Alabama, 미국, 36117
-
-
Arizona
-
Glendale, Arizona, 미국, 85306
-
Phoenix, Arizona, 미국, 85006
-
-
California
-
Chula Vista, California, 미국, 91911
-
Lomita, California, 미국, 90717
-
Long Beach, California, 미국, 90822
-
Mission Viejo, California, 미국, 92691
-
Oceanside, California, 미국, 92056
-
Palo Alto, California, 미국, 94304
-
Riverside, California, 미국, 92506
-
San Diego, California, 미국, 92117
-
San Jose, California, 미국, 95124
-
-
Colorado
-
Wheat Ridge, Colorado, 미국, 80033
-
-
Florida
-
Clearwater, Florida, 미국, 33765
-
DeBary, Florida, 미국, 32713
-
DeLand, Florida, 미국, 32720
-
Orlando, Florida, 미국, 32806
-
-
Georgia
-
Savannah, Georgia, 미국, 31406
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70115
-
-
Michigan
-
Taylor, Michigan, 미국, 48180
-
-
Nebraska
-
Omaha, Nebraska, 미국, 68198
-
-
New York
-
Buffalo, New York, 미국, 14215
-
Ithaca, New York, 미국, 14850
-
-
North Carolina
-
Greenville, North Carolina, 미국, 27834
-
-
Ohio
-
Columbus, Ohio, 미국, 43210
-
Maumee, Ohio, 미국, 43537
-
Toledo, Ohio, 미국, 43614
-
-
Oregon
-
Medford, Oregon, 미국, 97504
-
-
Rhode Island
-
Johnston, Rhode Island, 미국, 02919
-
-
South Carolina
-
Easley, South Carolina, 미국, 29640
-
Gaffney, South Carolina, 미국, 29340
-
Spartanburg, South Carolina, 미국, 29303
-
Union, South Carolina, 미국, 29379
-
-
Texas
-
San Antonio, Texas, 미국, 78212
-
-
Virginia
-
Richmond, Virginia, 미국, 23225
-
Salem, Virginia, 미국, 24153
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria (selected):
- > 40 years of age
- History of COPD
- Forced expiratory volume in 1 second (FEV1) </= 70% of predicted and FEV1/Forced vital capacity (FVC) </= 0.7 value at screening
- Have at least two acute exacerbation episodes in the proceeding year
- Clinically stable with no changes in health status within the last 30 days
- Lifetime smoking history of at least 10 pack-years
- Willing and able to use a daily electronic diary
Exclusion Criteria (selected):
- Use of any systemic or inhaled antibiotics within 30 days prior to baseline
- History of hypersensitivity to fluoroquinolones or intolerance with aerosol medication
- Creatinine clearance < 40 mg/ml/min, AST, ALT >/= 5 x upper limit of normal (ULN) or total bilirubin >/= 3 x ULN at Screening
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
위약 비교기: Placebo
Placebo inhaled twice daily via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
|
same frequency as study drug using the same method of delivery
다른 이름들:
|
실험적: MP-376 240 mg Twice Daily (BID)
MP-376 240 mg BID inhaled via the PARI eFlow nebulizer for 5 consecutive days within a 28-day treatment cycle for up to 12 cycles
|
MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Exacerbation Rate
기간: From randomization to the patients final study visit (up to 12 months)
|
The number of acute exacerbations per patient-year of study participation, where an acute exacerbation was defined as a deterioration in respiratory symptoms that required treatment with antibiotics, corticosteroids, hospitalization or a combination of those treatments.
|
From randomization to the patients final study visit (up to 12 months)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Duration of Acute Exacerbation
기간: from randomization to the patient's final study visit (up to 12 months)
|
From the beginning of antibiotics and/or systemic corticosteroids to the end of antibiotics and/or systemic corticosteroids, whichever was longer, for treatment of the first acute exacerbation
|
from randomization to the patient's final study visit (up to 12 months)
|
Percent Change in Forced Vital Capacity (FVC)
기간: from baseline to the conclusion of the fourth 28-day treatment cycle (4 months)
|
The percent change in the amount of air a patient can inhale
|
from baseline to the conclusion of the fourth 28-day treatment cycle (4 months)
|
Percent Change in Forced Expiratory Volume in 1 Second (FEV1)
기간: from baseline to the conclusion of the fourth 28-day treatment cycle (4 months)
|
The percent change in the amount of air a patient can exhale in 1 second
|
from baseline to the conclusion of the fourth 28-day treatment cycle (4 months)
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Sanjay Sethi, M.D., University at Buffalo
간행물 및 유용한 링크
일반 간행물
- Leidy NK, Murray LT, Monz BU, Nelsen L, Goldman M, Jones PW, Dansie EJ, Sethi S. Measuring respiratory symptoms of COPD: performance of the EXACT- Respiratory Symptoms Tool (E-RS) in three clinical trials. Respir Res. 2014 Oct 7;15(1):124. doi: 10.1186/s12931-014-0124-z.
- Leidy NK, Murray LT, Jones P, Sethi S. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014 Mar;11(3):316-25. doi: 10.1513/AnnalsATS.201309-305OC.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- Mpex-302
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Placebo에 대한 임상 시험
-
AJU Pharm Co., Ltd.OM Pharma SA모병
-
University Hospital, Strasbourg, France모집하지 않고 적극적으로